Previous Page  27 / 34 Next Page
Information
Show Menu
Previous Page 27 / 34 Next Page
Page Background

Page 64

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

16

th

EuroSciCon Conference on

Immunology

M a r c h 1 1 - 1 2 , 2 0 1 9

Am s t e r d a m , N e t h e r l a n d s

Immunology 2019

Background:

In this study, we investigated the associations of circulating long non-coding RNA (lncRNA) Tmevpg1, transcription

factor T-bet and IFN-γ cytokine relative expressions with severity and occlusion rate of coronary artery disease (CAD) patients.

Methods:

Sixty-four patients suspected of CAD who underwent coronary angiography were consecutively enrolled in this study

and divided into four group CAD 2, 3, 4 patients (N = 48) and CAD1 or controls (N=16) according to coronary angiographic results

and Gensini Score. Blood samples of all participants were collected. Quantitative polymerase chain reaction (qPCR) was used to

measure lncRNA Tmevpg1, transcription factor T-bet and IFNG cytokine expressions in whole blood samples. Serum interferon

gamma (IFN-γ) was evaluated using enzyme-linked immunosorbent assay (ELISA). Gensini Score was used to assess the disease

intensify and occlusion rate of CAD patients.

Results:

LncRNA Tmevpg1 relative expression in CAD patients was upregulated compared with that in controls (P<0.003).

LncRNA Tmevpg1 relative expression was remarkably associated with Gensini Score (P<0.01). Additionally, IFNG expression

and IFN-γ serum levels were significantly increased (P<0.001), while, T-bet expression was not significantly increased. (P=0.06).

Conclusion:

lncRNA Tmevpg1 and INF-γ expression correlated with higher disease severity, elevated inflammation and occlusion

rate in CAD patientS.

Gheitasi.r@yahoo.com

LncRNA Tmevpg1 expression and IFN

γ

correlates

with higher disease severity and occlusion

rate according to Gensini Score in patients with

coronary artery disease

Reza Gheitasi and Hamed Manochehry

Hamedan University of Medical Sciences, Iran

J Clin Immunol Allergy 2019, Volume:5

DOI: 10.21767/2471-304X-C1-009